AimsTo investigate whether the positive effects on glycaemic outcomes of 3‐month automated insulin delivery (AID) achieved in 2‐ to 6‐year‐old children endure over an extended duration and how AID treatment affects time in tight range (TITR), defined as 3.9–7.8 mmol/L.Research Design and MethodsWe analysed 18 months of follow‐up data from a non‐randomized, prospective, single‐arm clinical trial (n = 35) conducted between 2021 and 2023. The main outcome measures were changes in time in range (TIR), glycated haemoglobin (HbA1c), time above range (TAR), TITR, and mean sensor glucose (SG) value during follow‐up visits (at 0, 6, 12 and 18 months). The MiniMed 780G AID system in SmartGuard Mode was used for 18 months. Parental diabetes distress was evaluated at 3 and 18 months with the validated Problem Areas in Diabetes—Parent, revised (PAID‐PR) survey.ResultsBetween 0 and 6 months, TIR and TITR increased, and HbA1c, mean SG value and TAR decreased significantly (p < 0.001); the favourable effect persisted through 18 months of follow‐up. Between 3 and 18 months, PAID‐PR score declined significantly (0 months: mean score 37.5; 3 months: mean score 28.6 [p = 0.06]; 18 months: mean score 24.6 [p < 0.001]).ConclusionsTreatment with AID significantly increased TITR and TIR in young children. The positive effect of AID on glycaemic control observed after 6 months persisted throughout the 18 months of follow‐up. Similarly, parental diabetes distress remained reduced during 18 months follow‐up. These findings are reassuring and suggest that AID treatment improves glycaemic control and reduces parental diabetes distress in young children over an extended 18‐month follow‐up.

中文翻译：

---

在为期 18 个月的自动胰岛素输送治疗过程中，2 至 6 岁的儿童在小范围内达到并保持了较高的时间

目的 调查 3 个月自动胰岛素输送 (AID) 对 2 至 6 岁儿童的血糖结果的积极影响是否持续较长时间，以及 AID 治疗如何影响紧密范围时间 (TITR)，定义为3.9–7.8 mmol/L。研究设计和方法我们分析了一项非随机、前瞻性、单臂临床试验的 18 个月随访数据（n= 35）在 2021 年至 2023 年间进行。主要结果指标是随访期间范围内时间 (TIR)、糖化血红蛋白 (HbA1c)、超出范围的时间 (TAR)、TITR 和平均传感器葡萄糖 (SG) 值的变化访视（0、6、12 和 18 个月时）。 SmartGuard 模式下的 MiniMed 780G AID 系统已使用 18 个月。在 3 个月和 18 个月时，通过经过验证的糖尿病问题领域——家长修订版 (PAID-PR) 调查来评估父母的糖尿病困扰。结果在 0 个月和 6 个月之间，TIR 和 TITR 增加，HbA1c、平均 SG 值和 TAR 显着下降（p< 0.001);在 18 个月的随访中，良好的效果持续存在。 3 至 18 个月期间，PAID-PR 评分显着下降（0 个月：平均评分 37.5；3 个月：平均评分 28.6 [p= 0.06]; 18 个月：平均分 24.6 [p< 0.001])。结论AID 治疗显着增加幼儿的 TITR 和 TIR。 6 个月后观察到的 AID 对血糖控制的积极作用在整个 18 个月的随访中持续存在。同样，在 18 个月的随访期间，父母的糖尿病困扰仍然减少。这些发现令人放心，表明在长达 18 个月的随访中，AID 治疗可改善幼儿的血糖控制并减少父母的糖尿病困扰。